Introduction
As a source of hematopoietic cells, the utilization of umbilical cord blood (UCB) for transplantation is expanding (1, 2) . The ability to conduct UCB transplantation using human leukocyte antigen (HLA) disparate donors with a reduced risk of severe graft-versus-host disease compared to established sources of hematopoietic cells such as bone marrow effectively extends the possibility of transplantation to those who lack a suitable HLA-matched family-or unrelated donor. The principal limitation of UCB transplantation is its cellular content, and with donor-recipient HLA compatibility represents the most important determinant of outcome after UCB transplantation. This limitation has prompted the development of clinical protocols using 2 UCB units for transplantation of larger adult recipients (3, 4) . An alternate approach is to develop methods to increase the cellular yield of hematopoietic cells similar to those in UCB. It was shown that the mouse placenta is a source for hematopoietic cells (5, 6) . Here, for the first time we show the presence of significant amounts of viable hematopoietic cells in human term placenta. These placental hematopoietic cells (PHCs) can be isolated before and after cryopreservation and storage. The colony-forming unit (CFU) activity of PHCs was confirmed, and xenotransplantation assays in immunocompromised mice demonstrated the potential of these placental cells for engraftment. Together, these results strongly suggest that the human term placenta has the potential to become a novel source of hematopoietic cells for transplantation.
chloride, 1 mg/mL) at room temperature. The arteries and vein of the umbilical cord were subsequently cannulated, and connected to a perfusion circuit, containing a heat exchange unit, roller pump and perfusion reservoir. Constant temperature of the perfusate was maintained, perfusion procedures were performed similarly as described by us before (7) , and the placentas were first perfused with phosphate buffered saline (PBS) to remove UCB remaining in the placental tissue. Long-term perfusions (6 hours) were performed with 500-1000 mL of alfa-MEM medium containing 5% bovine serum albumin (Sigma, St. Louis, MO), 10 U/mL heparin and 0.1 mg/mL Papaverin hydrochloride. For cryopreservation, placentas were perfused with a mixture of 15% propylene glycol, 14% DMSO, 14% Formamide, and 57% PBS with Penicillin 100 U/mL/ Streptomycin 100 lg/mL/Fungisone 0.25 lg/mL (PSF). The arterial and venous lines were then closed, placentas were placed into a À808C freezer for 12 hours, and subsequently placed into liquid nitrogen vapor at À1908C for long-term storage.
Immunostaining. Tissues were fixed with 4% paraformaldehyde, paraffin-fixed and cut, deparaffinized in Xylenes, re-hydrated in alcohols, permeabilized with cold Methanol (À208C) and 1% Triton X-100 for 5 minutes. Slides were incubated with blocking buffer (3% BSA in 4x SCC, 2% goat serum, 3% FCS, 0.1% Tween 20) for 60 minutes at 378C and incubated with primary antibody (1:10-100 dilution) overnight at 48C. Slices were washed, incubated with blocking solution for 20 minutes and then incubated with secondary antibody (1:500) labeled with FITC-or Alexa Fluor-633 for 60 minutes at 378C, washed, and mounted on slides with Gold Antifade reagent (Molecular Probes, Eugene, OR). The following antibodies were used: mouse anti-human CD34 (BD Pharmingen, San Jose, CA, Cat# 555820), mouse anti-human CD31 (Acris Antibodies GmbH, Germany, Cat# BM4047), rabbit antihuman CD133 (Abcam, Cambridge, MA, Cat# ab16518), mouse anti-human CD90 (BD Pharmingen, Cat# 550402), mouse anti-human CD38 (BD Pharmingen, Cat# 555458), mouse anti-human KDR (R&D Systems, Cat# MAB3571), rat anti-human HLA-DR (Serotec, Cat# MCA71F). Isotype anti-mouse and anti-rabbit antibodies were from Zymed (S. San Francisco, CA), secondary anti-mouse and anti-rabbit FITC-or Alexa Fluor 633-labeled antibodies were from Molecular Probes (Invitrogen). Microscopic images were obtained with an Olympus IX70 inverted microscope (Olympus), CoolSNAPfx camera (Roper Scientific) and QED Acquisition software (Media Cybernetics). Merged images were prepared using Photoshop CS3 software (Adobe).
Placental Cell Isolation. Cells were isolated from placental tissue by either enzyme digestion or perfusion with AMD 3100. Portions of the perfused and washed placenta were infused with 50 mL PSF containing 2.5 U/mL Dispase, Trypsin (0.5 mg/mL) for 20 minutes at 378C, and tissue samples were digested with 0.1% Collagenase I, and 2.5 U/mL Dispase. Alternatively, following perfusion as described above with phosphate buffered saline (PBS) to remove UCB remaining in the placental tissue, the specific blocker of the CXCR-4 receptor (8, 9), 1,19-[1,4-Phenylenebis(methylene)] bis-1,4,8,11-tetraazacyclotetradecane octahydro-chloride (AMD 3100, Sigma-Aldrich, St. Louis, MO, USA) was added to the perfusate at concentration 300 microgram per liter. Perfusion was continued up to 6 hours. Following centrifugation, the cells from tissue digest or placental perfusate were re-suspended in growth medium in Petri dishes or analyzed by flow cytometry.
Hematopoietic Differentiation Assays. Colonies of cells were scored for CFU-E, BFU-E, CFU-GM, and CFU-GEMM after incubation for 2 weeks with complete MethoCultt Methylcellulose-based media (Stem Cell Technologies, Vancouver, Canada).
FACS Analysis. The Procount Progenitor Cell Enumeration Kit (BD Biosciences) containing fluorochrome-conjugated monoclonal antibodies directed against CD34 and CD45, in combination with the viability stain ToPro-3 iodide (Molecular Probes, Eugene, OR), was used to determine live CD34 þ CD45 þdim cells in cord blood, tissue digests and placental perfusate using a FACSCalibur flow cytometer (BD Biosciences) and FlowJo analysis software (Tree Star, Inc., Ashland, OR). Antibodies against KDR (R&D Systems, Cat# MAB3571) and CD31 (AbCam, Cat# ab59251) and CD133 (AbCam, Cat# ab16518) were used to identify cells in this population positive for these endothelial markers. In addition, fluorochrome-conjugated monoclonal antibodies directed against CD3 (PE-conjugated, Miltenyi Biotec, Cat# 130-091-374), CD25 (PEconjugated, Miltenyi Biotec, Cat# 120-001-311), CD45 (APC-conjugated, Caltag Laboratories, Cat# MHCD4505), CD51/61 (BD Pharmingen, Cat# 550037) and CD235 (Dako, Denmark, Cat# R7078) were used to characterize cells in cell culture of mouse tissue. From the concentration in the weighed and digested fractions of placental tissue, the total number of these cells present in the total placenta was estimated by extrapolation to the total weight of the placental tissue. Similarly, the concentration of nucleated and viable CD34 þ CD45 þdim expressing cells was determined in the unit of UCB collected from the same placenta. The total number of these cells in the unit of UCB was estimated by extrapolation from the concentration in the measured volume to the total volume of UCB collected.
Chimeric Mice. Nonirradiated NOD-Cg-
Prkdcscid
Il2rgtm1Wjl/SzJ , and 2.5 Gy total-body irradiated NODCgRag1tm1Mom Prf1tm1Sdz/Sz mice (The Jackson Laboratory, Bar Harbor, Maine) were injected via the intra-peritoneal (IP) route with 10 6 nucleated cells prepared from digested placental tissue. After 3 months and weekly IP injection with erythropoietin (1 U), IL-3 (5 ng), stem cell factor (25 ng) and GM-CSF (5 ng) IP, the animals were sacrificed, and blood, bone marrow, and spleen cells were immunostained for human CD45 (pan-leukocyte), CD3 (lymphocyte), CD25 (lymphocyte/monocyte), and CD51-CD61 (platelet).
Blood was analyzed by flowcytometry, and tissue by fluorescent microscopy. Non-transplanted mouse tissue and human blood cells were used as negative and positive controls, respectively.
Results and Discussion
Paraffin sections of the chorion of term human placentas were stained with 3,3-diaminobenzidine for the CD34 antigen. As shown in Figure 1 , we found CD34-expressing cells in the vessels and vessel walls as well as in the tissue stroma. These cells are indicated in Figure 1 by white and dark arrows, respectively. This data suggested the presence of CD34-expressing endothelial cells in the vessel wall, as well as non-endothelial CD34-expressing cells in tissue not related to vessels.
As shown in Figure 2 , significant numbers of CD34-expressing cells are also positive for other hematopoietic precursor markers such as CD90, CD38 and CD133. These data observed using a microscope are evidence of the presence of multiple clusters of CD34-expressing cells, not associated with the fetal or maternal circulation.
The white arrow in Figure 2A3 indicates a cell positive for both CD34 and CD90. Figure 2B3 shows cells that express both CD34 and CD38, and Figure 2C3 indicates the presence of CD34-expressing cells positive for CD133. Because CD34 and CD133 antigens are expressed by endothelial cells as well as by hematopoietic cells, we investigated whether CD34 and CD133-expressing cells present in the mesenchyme of human placenta were also positive for the endothelial markers CD31 and KDR (also known as the vascular endothelial growth factor receptor VEGFR2, or CD309). Hematopoietic cells are positive for CD34 and or CD133, but do not express CD31 or KDR. Figure 3 shows dual staining for CD34 and CD133, as well as CD31, and KDR. Distinct populations that express both CD34 and CD31 (indicative of endothelial cells), and distinct populations expressing CD34 but not CD31 (indicative of hematopoietic cells) were found. Similarly cells that express CD34, but not KDR (indicative of hematopoietic cells), were found to be present. Also cells were present that express CD133 but not CD31 (indicative of hematopoietic cells). Figure 3A and B shows cells that express CD34 but not CD31, as well as cells that express both CD34 and CD31. Similarly Figure 3C shows cells that express CD34 but not KDR, as well as cells that express both CD34 and KDR. Co-staining for CD31 and CD133 shows some cells that express CD133 but not CD31, but also cells that express only CD31, and not CD133. This is further illustrated in supplemental Figure 1 (available in the online version).
The compilation of these data shows that the chorion of the human term placenta contains clusters of hematopoietic cells that are not associated with fetal or maternal circulation, and are separate from the CD34-expressing endothelial cells. Having shown the presence of these cells in the placental chorion, we pursued different approaches to harvest these cells, define their characteristics by flow cytometry, and test their viability in cell culture and a murine transplant model. Enzymatic digestion of placental tissue generated cell suspensions that could be analyzed by flow cytometry. The measurement of CD34 in combination with CD45 is routinely used to characterize cord blood. Using the Procount Progenitor Cell Enumeration Kit (BD Biosciences) in combination with the viability stain ToPro-3 iodide (Molecular Probes, Eugene, OR), we identified live CD34 þ CD45 þdim cells in the suspension of random chorion samples from 20 human placentas before and after cryopreservation. Perfusion of the placenta before enzyme digestion minimized residual cord blood in the placenta.
A similar analysis was performed on cord blood collected from the same placentas. Forward/side scatter and ToPro-3 labeling was used to select live cells, and CD34
þ CD45 þdim cells were identified and enumerated by the inclusion of fluorescent beads in the suspension. A typical example of such an analysis is shown in Figure 4A . Figures 2 and 3 . To demonstrate the human placenta as a source of hematopoietic cells and to evaluate an alternative way to harvest these cells, we used AMD 3100, a bicyclam, which is an antagonist of the CXCR-4 Chemokine Receptor. This compound was used in humans (8) and nonhuman primates (9) to mobilize hematopoietic stem cells into peripheral blood with long-term repopulating capacity. We proposed that this specific blocker of the CXCR-4 receptor could have a similar affect on mobilizing hematopoietic stem cells from human placenta. Four separate placentas were drained of cord blood and perfused with buffer, to remove cord blood remnants. Subsequently they were perfused with a set volume of buffer, and the cell content in the perfusate buffer was measured by flow cytometry as shown in Figure 4 . Similar to the analysis of digested placental tissue, forward/side scatter and ToPro-3 labeling was used to select live cells (not shown). In this live cell population, CD34 þ CD45 þdim cells were identified and enumerated by the inclusion of fluorescent beads in the suspension, using the same approach as shown for placental digest in Figure 4A . After 30-60 minutes of perfusion and before the addition of AMD 3100 to the perfusate buffer, we measured approximately 1 3 10 6 nucleated cells per mL in the perfusate buffer, a fraction of which were live CD34 þ /CD45 dim cells (Table 1) . Six hours after addition of 300 lg/L AMD 3100 to the perfusate buffer, the concentration of live CD34 AMD 3100 were negative for the endothelial markers KDR and CD31. Figure 4B and C illustrates flow cytometric analysis of cells in perfusate labeled with CD34, CD45, CD31, and KDR. Figure 4B shows the total population of cells in perfusate labeled with antibodies against CD34 and CD45. The CD34 þ /CD45 dim population is indicated in the selection box. In this population, more than 99% of the cells are negative for CD31 and KDR (Fig. 4C) . Similar results are found for the co-localization of CD133 and KDR (not shown). These data indicate that perfusion of the human term placenta with a compound that is currently used to release donor hematopoietic cells into the peripheral blood can be used to harvest hematopoietic CD34 þ /CD45 dim cells from tissue. The total amount of these cells harvested compares favorably with reported data on cord blood CD34 þ cells (10). The ability to form blood cell-forming colonies in cell culture is an essential characteristic of the potential of CD34 þ /CD45 dim cells to be used in transplant. We performed standard colony-forming analyses in MethoCultt medium to evaluate the viability and ability of placentalderived cells to differentiate, after placenta digestion or perfusion. The placental cells generated a large number of colonies, including CFU-E (colony forming unit erythroid), BFU-E (burst-forming unit erythroid), CFU-GM (colony forming unit-granulocyte, macrophage), CFU-GEMM (colony forming unit-granulocyte, erythroid, macrophage, megakaryocyte). Colonies generated from placenta and UCB showed a similar microscopic appearance (Fig. 5A) , and expressed hemoglobin (Fig. 5B) .
To ensure that these colonies were of fetal and not maternal origin, we analyzed colonies generated from male placentas for the presence of the Y chromosome. The cultured colonies were more than 90% positive for the Ychromosome, as measured using FISH with Y-chromosome paint (Cambio, UK). This is the upper limit of detection by this technique, and indicated that the colonies grown originate from cells harvested from the fetal side of the placenta. Cells derived from placentas after cryopreservation generated similar results in cell culture (Fig. 5C, D) .
Following a 2-week culture in Methocult mediumt, cells isolated from placental tissue were further characterized by flow cytometry and showed the presence of myeloid and erythroid lineages. Representative flow cytometry diagrams of cells isolated from culture medium and stained for human CD45 (pan leukocyte marker), CD25 (lymphocyte/monocyte marker), CD51/CD61 (megakaryocyte/platelet marker), and CD235 (human glycophorin A) are shown in Figure 5E . Double staining for human CD45 and CD25 shows the white cell lineage (Fig. 5E2) , double staining for CD45 and CD51/CD61 indicates the platelet lineage (Fig.  5E3) , and staining for CD235 indicates the erythroid lineage (Fig. 5 E4) . Together these data indicate that cells from placental tissue differentiated into all hematopoietic lineages in vitro.
To enumerate colony forming units generated from placental cells, we determined the number of colonies formed from cells collected from perfusates before and after AMD 3100 treatment. The colonies were counted 14 days after the start of the culture, and Table 1 indicates the total CFU count as well as the CFU-E and CFU-GM count in these cultures per mL of perfusate used. The appearance of these colonies was as indicated in Figure 5A . The total CFU count generated from 1 mL of perfusate increased approximately 9-fold (from 240 to 1800 per ml) before and 6 hours after AMD 3100 treatment, respectively. Together, these data show that perfusion of human placentas with AMD 3100 leads to the release of CD34 þ /CD45 dim cells in perfusate, that these cells are negative for endothelial markers, and that perfusate contains an abundant number of colony forming cells.
It was reported that in human stem cell donors, infusion of 40-80 lg AMD 3100/kg body weight leads to an increase in hematopoietic stem cells in the peripheral blood that can be harvested and used for stem cell transplant (8) .
Similarly primate studies showed the use of 1000 lg/kg body weight (9) for the release of these cells into the circulation. While a direct comparison between perfusate volume, placental weight, body weight and circulating blood volume is complex, we attempted to use concentrations of this compound that approximated those used in human and primate studies (8, 9) . Our data shows that AMD 3100 at 300 lg/L will release cells into the perfused circulation of the placenta in a timeframe similar for the release of such cells from bone marrow into peripheral blood of human or primate (8, 9) . We, therefore, conclude that stem cell niches in placental circulation may act similarly as compared to bone marrow with respect to the ability of AMD 3100 to mobilize hematopoietic stem cells. Perfusate before AMD 3100 treatment 1.0 6 0.3 600 6 500 90 6 70 90 6 30 240 6 10 Perfusate 6 hours after AMD 3100 treatment 4.7 6 3.0 2500 6 100 600 6 200 500 6 200 1800 6 700 a Total nucleated cell count (TNC), and live CD34 þ /CD45 dim collected in 750 6 100 mL perfusate are indicated as well as the number of colony forming units (CFU) generated by these cells in cell culture (n ¼ 4, 6 SD).
The use of this compound was recently approved by the FDA for routine use in humans (11) . Our data indicate that the use of this compound offers a viable alternative to harvest hematopoietic stem and progenitor cells from placenta to be used in transplant protocols.
To show the potential of placenta-derived cells to engraft after transplantation, immunodeficient mice were injected with the same placental-derived cells that showed the potential to form colony forming units in cell culture. We did not select subpopulations. We argued that the selection of specific subpopulations may have excluded phenotypically yet uncharacterized hematopoietic stem and progenitor cells from placenta. We followed, therefore, a similar approach as pursued with human cord blood transplants in immunodeficient mice (12) , and injected an unseparated cell population. Injection of more than 5 3 10 5 cells/animal IV from digested placental tissue caused lung embolism and death in some animals (data not shown). To avoid this, we used well tolerated IP injections of these cell preparations. Three mice, not exposed to radiation treatment, were injected with cell suspensions derived from human placental chorion. In one mouse, the bone marrow showed the presence of 0.2% human CD45-expressing cells 80 days post-transplant; the two other mice showed no human CD45 expressing cells in either bone marrow or blood 80 days post-transplant.
This low level of engraftment confirms reported data that engraftment in xenotransplants in non-irradiated mice is very low (12) . Mice exposed to 2.5 Gy total body irradiation one day before injection with human placenta-derived cells showed engraftment of human cells. Microscopic analysis of murine spleens 80 days post-injection showed cells positive for human CD45 and human HLA-DR ( Figure 6A-C) . Mouse blood, bone marrow and spleen were further analyzed by flow cytometry for the presence of human cells. Typical flow cytometric results of engraftment in the mouse spleen are shown in Figure 6D . Similarly flow cytometric analysis indicated the presence of human cells in blood and bone marrow. Table 2 shows the typical results of presence of cells that express human CD45 in three individual mice. Blood, bone marrow and spleen were double-positive for CD45/ CD3, CD45/CD25, and CD45/CD51/CD61 cells. While bone marrow of these mice showed the presence of erythroid precursors (positive for CD235), human eryth- rocytes were not observed in peripheral blood, confirming similar results reported for cord blood transplant (12) . Apparently the microenvironments in the hematopoietic organs or the circulation of these mice are not compatible with human adult red cells. Thus, NOD/SCID mice demonstrated chimerism for human blood cells following transplantation of placenta-derived cells similar as reported for transplantation with human cord blood (13) . Importantly, our data do not allow direct comparison with cord blood transplants or provide optimized transplant conditions. The experiments were designed to prove the principle that human placental-derived cells are able to engraft immunodeficient animals. Together our data shows that the human term placenta harbors hematopoietic cells similar as was reported for murine placenta. Studies performed in mice demonstrated that during development, hematopoietic stem cells originate in aorta-gonad-mesonephros region of the embryo (14-16), and could also be derived from embryonic arteries (17) . These hematopoietic stem cells colonize the liver, which subsequently becomes the major site of hematopoiesis at the later stages of gestation in the mouse. The aorta-gonadmesonephros was considered the primary site of origin of hematopoietic stem cells (18) until placenta was discovered to harbor multiple multi-potent progenitors of blood cells and primitive hematopoietic stem cells in mice (19) (20) (21) . Alvarez-Silva et al. (19) reported that mouse placenta is several-fold richer in hematopoietic stem cells than liver early in murine development. The early appearance of hematopoietic stem cells suggests that placenta is a hematopoietic organ, and the most likely origin of these cells is the mesoderm of allantois. The rapid proliferation of hematopoietic stem cells suggests unique conditions for hematopoiesis in placenta (5) . It is yet unknown whether placenta is the site at which these cells reside temporarily on their journey to the liver, or if placenta is the site of hematopoietic stem cell proliferation (6) . Later during mouse development, the numbers of hematopoietic stem cells decline in mouse placenta, while they increase in liver (5), and they express the same phenotype in either tissue. While erythropoiesis in mouse placenta is less pronounced than in liver, precursors of B-lymphocytes appear in murine placenta before they can be found in liver indicating that murine placenta is a myeloid organ (5, 22) . Our data show that the human term placenta, similar to the mouse placenta, contains hematopoietic stem-and progenitor cells. We show that it is possible to cryopreserve and thaw whole human placentas, and recapitulate hematopoiesis with cells obtained from human placental tissue. We show that AMD 3100, a compound used to mobilize hematopoietic stem cells in humans, also mobilizes such cells from placenta by perfusion. We believe therefore that the placenta has the potential to serve as a source of hematopoietic cells for transplantation to augment the cellular yield of UCB collections. This approach would be an alternative to protocols that use two unrelated UCB units for allogeneic hematopoietic cell transplantation (3, 4) . Several important additional assessments must be completed before a clinical trial using placenta cells becomes practical. Therefore, we have initiated efforts to study the sterility, potency, and reproducibility of large-scale placental harvest and storage. The ability to process placental hematopoietic cells has the potential to transform the clinical application of fetal hematopoietic stem cell transplantation, making this therapeutic option available to many more who might benefit from a transplantation, especially larger children, adolescents and adults.
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Note in press:
During the printing process, Barcena et al. published an online report (24) , which confirms our findings on the presence of hematopoietic cells in term human placenta. Based on their digestive collection procedure, which cannot exclude endothelial lineage, they estimate only 10 5 CD34
+ , CD45 dim cells in term placenta. The viability of these cells was not tested in a transplant model.
In this report we show that perfusion is able to generate an order of magnitude more CD34 + , CD45
þdim cells from term placenta, that these cells are not of endothelial lineage, and that these cells are viable both in cell culture and in a murine transplant model. Based on the numbers of hematopoietic cells harvested, our study indicates that the term human placenta should be considered as a practical resource for stem cell transplantation.
